Last deal

$27.93M
Local Amount - GBP 18M

Amount

Series B

Stage

23.07.2015

Date

1

all rounds

$27.93M

Total amount

date founded

Financing round

General

About Company
Blue Earth Diagnostics develops imaging agents for brain and prostate cancer.

Industry

Sector :

Subsector :

Keywords :

founded date

01.03.2014

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

The company's success is driven by its management expertise and rapid development and commercialization of PET radiopharmaceuticals. Their expanding oncology portfolio includes prostate cancer and neuro-oncology, and they are committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.
Contacts

location

Contact Email

Phone number

Social url

Similar Companies
1000
Amadix

Amadix

Amadix develops breakthrough cancer diagnosis products to solve unmet medical needs in oncology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Madrid, Spain

total rounds

5

total raised

$8.12M
Cernostics

Cernostics

Cernostics is a life science company that develops molecular diagnostic tests to fight cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Life Science, Health Care

Location

Danville, PA 17821, USA

total rounds

12

total raised

$21.26M
Swiss Nuclides

Swiss Nuclides

Swiss Nuclide AG develops affordable personalized precision diagnostics and therapy for cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology

Location

Aarau, Switzerland

total rounds

1

total raised

$2.9M
Chapter Diagnostics

Chapter Diagnostics

Cha Chapter Diagnostics is a company that develops core technologies to improve diagnostics for infectious diseases and cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Health Diagnostics

Location

Menlo Park, CA, USA
M&A Details
1

Acquired by

Bracco Diagnostic Imaging

announced date

27.06.2019

price

$450M

Financials

Funding Rounds
1
1

Number of Funding Rounds

$27.93M

Money Raised

Their latest funding was raised on 23.07.2015. Their latest investor Syncona Partners LLP. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 
23.07.2015
1
$27.93M
Local Amount - GBP 18M
Syncona Partners LLP

Syncona Partners LLP

Syncona Partners LLP is a healthcare company that invests in and builds global leaders in life science.

Sector

Health Care Providers

Subsector

Health Care Services

Keywords

Health Care, Financial Services, Venture Capital

Location

London, UK

count Of Investments

41

count Of Exists

4
Co-Investors
Investors
1
1

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series B
Syncona Partners LLP

Syncona Partners LLP

Syncona Partners LLP is a healthcare company that invests in and builds global leaders in life science.

Sector

Health Care Providers

Subsector

Health Care Services

Keywords

Health Care, Financial Services, Venture Capital

Location

London, UK

count Of Investments

41

count Of Exists

4

People

Founders
1
Jonathan Allis
Jonathan Allis

Jonathan Allis

Jonathan Allis is the founding CEO of Blue Earth Diagnostics. Prior to this role, Jonathan was the General Manager for PET at GE Healthcare Life Sciences, and had global responsibility for GE Healthcare’s PET agent and PET synthesis platforms business. He has previously held positions in R&D, Marketing and Product Development at GE Healthcare, Amersham plc., Siemens Medical Solutions and Oxford Magnet Technology, in the UK, USA and Germany. Jonathan has an undergraduate degree in Physics from the University of Cape Town and a doctorate in biochemistry from the University of Oxford.

current job

Blue Earth Diagnostics
Blue Earth Diagnostics

organization founded

1

Jonathan Allis

Employee Profiles
1
Jonathan Allis

Jonathan Allis

Co-Founder & CEO

Activity

Recent News
11
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week